Publications
5491 Results
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 9532); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Research Committee(s)
- Lung
- Study Number(s)
- S1403
Residual circulating tumor DNA (ctDNA) after two months of therapy predicts progression-free and overall survival in patients treated on SWOG S1403 with afatinib +/- cetuximab
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 5022); American Society of Clinical Oncology 2020 Annual Meeting, poster discussion
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1605
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605 (NCT #02844816)
- Journal / Conference
- Leukemia & Lymphoma Oct;61(10):2442-2447
- Year
- 2020
- Research Committee(s)
- Lymphoma
- PMID
- PMID32452714
- Study Number(s)
- S0816
Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: a Secondary Analysis of SWOG S0816
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 5523); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 5506); American Society of Clinical Oncology 2020 Annual Meeting, oral
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 4003);American Society of Clinical Oncology Annual Meeting (5/29/2020 - 6/2/2020, Chicago, IL), oral
- Year
- 2020
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80702
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 10039); American Society of Clinical Oncology Annual Meeting (5/29/2020 - 6/2/2020, Chicago, IL), poster
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1320
Association of Prior immune anti-PD-1 antibody therapy with longer progression free survival in patients treated with intermittent versus continuous dabrafenib and trametinib: a post-hoc analysis of S1320
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr LBA3); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary
- Year
- 2020
- Research Committee(s)
- Myeloma
- Study Number(s)
- CTSU/E1A11
Carfilzomib, lenalidomide and dexamethasone (KRd) versus Bortezomib, lenalidomide and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase 3 trial
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr LBA2); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), oral, plenary
- Year
- 2020
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/E2108
A randomized Phase Ill trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo Stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108)
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr e22078); American Society of Clinical Oncology Annual Meeting (5/29-6/2/20, Chicago, IL), publication only
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1609